Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate.

@article{Vaudo2016EarlyOnset5T,
  title={Early-Onset 5-Fluorouracil Toxicity in a Patient Negative for Dihydropyrimidine Dehydrogenase Mutations: The Clinical Course of Reversal with Uridine Triacetate.},
  author={Christine E Vaudo and Brigitte Gil and Kari Galuski and Corrine Zarwan and Francis W Nugent},
  journal={Pharmacotherapy},
  year={2016},
  volume={36 11},
  pages={
          e178-e182
        }
}
An antimetabolite pyridine analog, 5-fluorouracil (5-FU), is used to treat solid tumors. Early toxicities may occur at standard doses of 5-FU due to dihydropyrimidine dehydrogenase (DPD) deficiency. Uridine triacetate, approved by the Food and Drug Administration in 2015, is an oral prodrug of uridine, a pharmacologic antidote for 5-FU toxicity. To our… CONTINUE READING